Review Article

Organ-on-Chip Devices towards Applications in Drug Development and Screening: A Review

[+] Author and Article Information
Christopher Uhl

Department of BioEngineering, Lehigh University, Bethlehem, Pennsylvania 18015, USA

Wentao Shi

Department of BioEngineering, Lehigh University, Bethlehem, Pennsylvania 18015, USA

Yaling Liu

Department of BioEngineering, Lehigh University, Bethlehem, Pennsylvania 18015, USA; Department of Mechanical Engineering and Mechanics, Lehigh University, Bethlehem, Pennsylvania 18015, USA

1Corresponding author.

ASME doi:10.1115/1.4040272 History: Received February 12, 2018; Revised May 02, 2018


As a necessary pathway to man-made organs, organ-on-chips which simulate the activities, mechanics and physiological responses of a real organs have attracted plenty of attention over the past decade. As the maturity of 3D cell-culture models and microfluidics advances, the study of organ-on-chips has made significant progress. This review article provides a comprehensive overview and classification of organ-on-chip microfluidics. Specifically, the review focuses on organ-on-chip systems capable of being used in pre-clinical drug screening and development. Additionally, the review highlights the strengths and weaknesses of each organ-on-chip system towards the goal of improved drug development and screening. The various organ-on-chip systems investigated throughout the review include, blood vessel, lung, liver, and tumor systems and the potential benefits which each provides to the growing challenge of high-throughput drug screening. Published organ-on-chip systems have been reviewed over the past decade (2007-2017) with focus given mainly to more recent advances and improvements within each organ system. Each organ-on-chip system has been reviewed on how closely and realistically it is able to mimic its physiological counterpart, the degree of information provided by the system towards the ultimate goal of drug development and screening, how easily each system would be able to transition to large scale high-throughput drug screening, and what further improvements to each system would help to improve the functionality, realistic nature of the platform, and throughput capacity.

Copyright (c) 2018 by ASME
Your Session has timed out. Please sign back in to continue.





Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging and repositioning the boxes below.

Related Journal Articles
Related eBook Content
Topic Collections

Sorry! You do not have access to this content. For assistance or to subscribe, please contact us:

  • TELEPHONE: 1-800-843-2763 (Toll-free in the USA)
  • EMAIL: asmedigitalcollection@asme.org
Sign In